1
|
Cotrin JC, Piergiorge RM, Gonçalves AP, Pereira JS, Gerber AL, de Campos Guimarães AP, de Vasconcelos ATR, Santos-Rebouças CB. Co-occurrence of PRKN and SYNJ1 variants in Early-Onset Parkinson's disease. Metab Brain Dis 2024; 39:915-928. [PMID: 38836947 DOI: 10.1007/s11011-024-01362-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Accepted: 05/24/2024] [Indexed: 06/06/2024]
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease globally, with a fast-growing prevalence. The etiology of PD exhibits a multifactorial complex nature and remains challenging. Herein, we described clinical, molecular, and integrative bioinformatics findings from a Brazilian female affected by Early-Onset PD (EOPD) harboring a recurrent homozygous pathogenic deletion in the parkin RBR E3 ubiquitin protein ligase gene (PRKN; NM_004562.3:c.155delA; p.Asn52Metfs*29; rs754809877), along with a novel heterozygous variant in the synaptojanin 1 gene (SYNJ1; NM_003895.3:c.62G > T; p.Cys21Phe; rs1486511197) found by Whole Exome Sequencing. Uncommon or unreported PRKN-related clinical features in the patient include cognitive decline, auditory and visual hallucinations, REM sleep disorder, and depression, previously observed in SYNJ1-related conditions. Moreover, PRKN interacts with endophilin A1, which is a major binding partner of SYNJ1. This protein plays a pivotal role in regulating the dynamics of synaptic vesicles, particularly in the context of endocytosis and recycling processes. Altogether, our comprehensive analyses underscore a potential synergistic effect between the PRKN and SYNJ1 variants over the pathogenesis of EOPD.
Collapse
Affiliation(s)
- Juliana Cordovil Cotrin
- Department of Genetics, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rua São Francisco Xavier, 524, PHLC - sala 501F, Maracanã, Rio de Janeiro, RJ, 20550-013, Brazil
| | - Rafael Mina Piergiorge
- Department of Genetics, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rua São Francisco Xavier, 524, PHLC - sala 501F, Maracanã, Rio de Janeiro, RJ, 20550-013, Brazil
| | - Andressa Pereira Gonçalves
- Department of Genetics, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rua São Francisco Xavier, 524, PHLC - sala 501F, Maracanã, Rio de Janeiro, RJ, 20550-013, Brazil
| | - João Santos Pereira
- Movement Disorders Section, Neurology Service, Pedro Ernesto University Hospital, Rio de Janeiro State University, Rio de Janeiro, Brazil
| | - Alexandra Lehmkuhl Gerber
- Bioinformatics Laboratory (LABINFO), National Laboratory for Scientific Computing (LNCC), Petrópolis, Brazil
| | | | | | - Cíntia Barros Santos-Rebouças
- Department of Genetics, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rua São Francisco Xavier, 524, PHLC - sala 501F, Maracanã, Rio de Janeiro, RJ, 20550-013, Brazil.
| |
Collapse
|
2
|
Cogan G, Daida K, Billingsley KJ, Tesson C, Forlani S, Jornea L, Arnaud L, Tissier L, LeGuern E, Singleton AB, Ferrien M, Gervais Bernard H, Lesage S, Blauwendraat C, Brice A. Long-read sequencing unravels the complexity of structural variants in PRKN in two individuals with early-onset Parkinson's disease. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2024:2024.05.02.24306523. [PMID: 38746197 PMCID: PMC11092742 DOI: 10.1101/2024.05.02.24306523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2024]
Abstract
Background PRKN biallelic pathogenic variants are the most common cause of autosomal recessive early-onset Parkinson's disease (PD). However, the variants responsible for suspected PRKN- PD individuals are not always identified with standard genetic testing. Objectives Identify the genetic cause in two siblings with a PRKN -PD phenotype using long-read sequencing (LRS). Methods The genetic investigation involved standard testing using successively multiple ligation probe amplification (MLPA), Sanger sequencing, targeted sequencing, whole-exome sequencing and LRS. Results MLPA and targeted sequencing identified one copy of exon four in PRKN but no other variants were identified. Subsequently, LRS unveiled a large deletion encompassing exon 3 to 4 on one allele and a duplication of exon 3 on the second allele; explaining the siblings' phenotype. MLPA could not identify the balanced rearrangement of exon 3. Conclusions This study highlights the potential utility of long-read sequencing in the context of unsolved typical PRKN- PD individuals.
Collapse
|
3
|
Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, Levine KS, Abubakar SA, Achoru CO, Vitale D, Adeniji OA, Agabi OP, Koretsky MJ, Agulanna U, Hall DA, Akinyemi RO, Xie T, Ali MW, Shamim EA, Ani-Osheku I, Padmanaban M, Arigbodi OM, Standaert DG, Bello AH, Dean MN, Erameh CO, Elsayed I, Farombi TH, Okunoye O, Fawale MB, Billingsley KJ, Imarhiagbe FA, Jerez PA, Iwuozo EU, Baker B, Komolafe MA, Malik L, Nwani PO, Daida K, Nwazor EO, Miano-Burkhardt A, Nyandaiti YW, Fang ZH, Obiabo YO, Kluss JH, Odeniyi OA, Hernandez DG, Odiase FE, Tayebi N, Ojini FI, Sidranksy E, Onwuegbuzie GA, D'Souza AM, Osaigbovo GO, Berhe B, Osemwegie N, Reed X, Oshinaike OO, Leonard HL, Otubogun FM, Alvarado CX, Oyakhire SI, Ozomma SI, Samuel SC, Taiwo FT, Wahab KW, Zubair YA, Iwaki H, Kim JJ, Morris HR, Hardy J, Nalls MA, Heilbron K, Norcliffe-Kaufmann L, Blauwendraat C, Houlden H, Singleton A, Okubadejo NU. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol 2023; 22:1015-1025. [PMID: 37633302 PMCID: PMC10593199 DOI: 10.1016/s1474-4422(23)00283-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Revised: 06/15/2023] [Accepted: 07/18/2023] [Indexed: 08/28/2023]
Abstract
BACKGROUND An understanding of the genetic mechanisms underlying diseases in ancestrally diverse populations is an important step towards development of targeted treatments. Research in African and African admixed populations can enable mapping of complex traits, because of their genetic diversity, extensive population substructure, and distinct linkage disequilibrium patterns. We aimed to do a comprehensive genome-wide assessment in African and African admixed individuals to better understand the genetic architecture of Parkinson's disease in these underserved populations. METHODS We performed a genome-wide association study (GWAS) in people of African and African admixed ancestry with and without Parkinson's disease. Individuals were included from several cohorts that were available as a part of the Global Parkinson's Genetics Program, the International Parkinson's Disease Genomics Consortium Africa, and 23andMe. A diagnosis of Parkinson's disease was confirmed clinically by a movement disorder specialist for every individual in each cohort, except for 23andMe, in which it was self-reported based on clinical diagnosis. We characterised ancestry-specific risk, differential haplotype structure and admixture, coding and structural genetic variation, and enzymatic activity. FINDINGS We included 197 918 individuals (1488 cases and 196 430 controls) in our genome-wide analysis. We identified a novel common risk factor for Parkinson's disease (overall meta-analysis odds ratio for risk of Parkinson's disease 1·58 [95% CI 1·37-1·80], p=2·397 × 10-14) and age at onset at the GBA1 locus, rs3115534-G (age at onset β=-2·00 [SE=0·57], p=0·0005, for African ancestry; and β=-4·15 [0·58], p=0·015, for African admixed ancestry), which was rare in non-African or non-African admixed populations. Downstream short-read and long-read whole-genome sequencing analyses did not reveal any coding or structural variant underlying the GWAS signal. The identified signal seems to be associated with decreased glucocerebrosidase activity. INTERPRETATION Our study identified a novel genetic risk factor in GBA1 in people of African ancestry, which has not been seen in European populations, and it could be a major mechanistic basis of Parkinson's disease in African populations. This population-specific variant exerts substantial risk on Parkinson's disease as compared with common variation identified through GWAS and it was found to be present in 39% of the cases assessed in this study. This finding highlights the importance of understanding ancestry-specific genetic risk in complex diseases, a particularly crucial point as the Parkinson's disease field moves towards targeted treatments in clinical trials. The distinctive genetics of African populations highlights the need for equitable inclusion of ancestrally diverse groups in future trials, which will be a valuable step towards gaining insights into novel genetic determinants underlying the causes of Parkinson's disease. This finding opens new avenues towards RNA-based and other therapeutic strategies aimed at reducing lifetime risk of Parkinson's disease. FUNDING The Global Parkinson's Genetics Program, which is funded by the Aligning Science Across Parkinson's initiative, and The Michael J Fox Foundation for Parkinson's Research.
Collapse
Affiliation(s)
- Mie Rizig
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
| | - Sara Bandres-Ciga
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | - Mary B Makarious
- UCL Movement Disorders Centre, University College London, London, UK; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | | | - Peter Wild Crea
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | | | - Kristin S Levine
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International, Washington, DC, USA
| | | | | | - Dan Vitale
- Data Tecnica International, Washington, DC, USA
| | | | - Osigwe Paul Agabi
- College of Medicine, University of Lagos, Idi Araba, Lagos State, Nigeria
| | - Mathew J Koretsky
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | - Uchechi Agulanna
- Lagos University Teaching Hospital, Idi Araba, Lagos State, Nigeria
| | - Deborah A Hall
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
| | - Rufus Olusola Akinyemi
- Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria
| | - Tao Xie
- Department of Neurology, University of Chicago Medicine, Chicago, IL, USA
| | | | - Ejaz A Shamim
- Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Kaiser Permanente Mid-Atlantic States, Largo, MD, USA; MidAtlantic Permanente Research Institute, Rockville, MD, USA
| | | | - Mahesh Padmanaban
- Department of Neurology, University of Chicago Medicine, Chicago, IL, USA
| | | | - David G Standaert
- Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - Marissa N Dean
- Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - Inas Elsayed
- Faculty of Pharmacy, University of Gezira, Wadmadani, Sudan
| | | | - Olaitan Okunoye
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
| | | | - Kimberley J Billingsley
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | | | - Pilar Alvarez Jerez
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK; Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | | | - Breeana Baker
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | | | - Laksh Malik
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | - Paul Osemeke Nwani
- Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria
| | - Kensuke Daida
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | | | - Abigail Miano-Burkhardt
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | | | - Zih-Hua Fang
- German Center for Neurodegenerative Diseases, Tuebingen, Germany
| | | | - Jillian H Kluss
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | | | - Dena G Hernandez
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | | | - Nahid Tayebi
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Francis Ibe Ojini
- College of Medicine, University of Lagos, Idi Araba, Lagos State, Nigeria
| | - Ellen Sidranksy
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | | | - Andrea M D'Souza
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | | | - Bahafta Berhe
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | | | - Xylena Reed
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | | | - Hampton L Leonard
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International, Washington, DC, USA
| | | | - Chelsea X Alvarado
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International, Washington, DC, USA
| | | | | | | | | | - Kolawole Wasiu Wahab
- University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria; University of Ilorin, Ilorin, Kwara State, Nigeria
| | | | - Hirotaka Iwaki
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International, Washington, DC, USA
| | - Jonggeol Jeffrey Kim
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | - Huw R Morris
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
| | - John Hardy
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | | | | | | | - Cornelis Blauwendraat
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | - Henry Houlden
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
| | - Andrew Singleton
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
| | - Njideka Ulunma Okubadejo
- College of Medicine, University of Lagos, Idi Araba, Lagos State, Nigeria; Lagos University Teaching Hospital, Idi Araba, Lagos State, Nigeria.
| |
Collapse
|
4
|
Alizadeh P, Terroba-Chambi C, Achen B, Bruno V. Pain in monogenic Parkinson's disease: a comprehensive review. Front Neurol 2023; 14:1248828. [PMID: 38020640 PMCID: PMC10643218 DOI: 10.3389/fneur.2023.1248828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 10/10/2023] [Indexed: 12/01/2023] Open
Abstract
Pain, a challenging symptom experienced by individuals diagnosed with Parkinson's disease (PD), still lacks a comprehensive understanding of its underlying pathophysiological mechanisms. A systematic investigation of its prevalence and impact on the quality of life in patients affected by monogenic forms of PD has yet to be undertaken. This comprehensive review aims to provide an overview of the association between pain and monogenic forms of PD, specifically focusing on pathogenic variants in SNCA, PRKN, PINK1, PARK7, LRRK2, GBA1, VPS35, ATP13A2, DNAJC6, FBXO7, and SYNJ1. Sixty-three articles discussing pain associated with monogenic PD were identified and analyzed. The included studies exhibited significant heterogeneity in design, sample size, and pain outcome measures. Nonetheless, the findings of this review suggest that patients with monogenic PD may experience specific types of pain depending on the pathogenic variant present, distinguishing them from non-carriers. For instance, individuals with SNCA pathogenic variants have reported painful dystonia, lower extremity pain, dorsal pain, and upper back pain. However, these observations are primarily based on case reports with unclear prevalence. Painful lower limb dystonia and lower back pain are prominent symptoms in PRKN carriers. A continual correlation has been noted between LRRK2 mutations and the emergence of pain, though the conflicting research outcomes pose challenges in reaching definitive conclusions. Individuals with PINK1 mutation carriers also frequently report experiencing pain. Pain has been frequently reported as an initial symptom and the most troublesome one in GBA1-PD patients compared to those with idiopathic PD. The evidence regarding pain in ATP13A2, PARK7, VPS35, DNAJC6, FBXO7, and SYNJ1pathogenic variants is limited and insufficient. The potential linkage between genetic profiles and pain outcomes holds promising clinical implications, allowing for the potential stratification of patients in clinical trials and the development of personalized treatments for pain in monogenic PD. In conclusion, this review underscores the need for further research to unravel the intricate relationship between pain and monogenic forms of PD. Standardized methodologies, larger sample sizes, and longitudinal studies are essential to elucidate the underlying mechanisms and develop targeted therapeutic interventions for pain management in individuals with monogenic PD.
Collapse
Affiliation(s)
- Parisa Alizadeh
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Hotchkiss Brain Institute, Calgary, AB, Canada
| | | | - Beatrice Achen
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
| | - Veronica Bruno
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- Hotchkiss Brain Institute, Calgary, AB, Canada
| |
Collapse
|
5
|
Smaili I, Tibar H, Rahmani M, Machkour N, Razine R, Darai HN, Bouslam N, Benomar A, Regragui W, Bouhouche A. Gene Panel Sequencing Analysis Revealed a Strong Contribution of Rare Coding Variants to the Risk of Parkinson's Disease in Sporadic Moroccan Patients. J Mol Neurosci 2023; 73:391-402. [PMID: 37256495 DOI: 10.1007/s12031-023-02128-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 05/24/2023] [Indexed: 06/01/2023]
Abstract
Parkinson's disease (PD) is a neurodegenerative movement disorder which can be either familial or sporadic. While it is well known that monogenic mutations are not a very common cause of PD, GWAS studies have shown that an additional fraction of the PD heritability could be explained by rare or common variants. To identify the rare variants that could influence the risk of PD in the Moroccan population, a cohort of 94 sporadic PD patients negative for the LRRK2 G2019S mutation was subjected to NGS gene panel sequencing, and gene dosage using the MLPA method. Mean age of onset at enrollment was 51.7 ± 11.51 years, and 60% of patients were men. We identified 70 rare variants under 0.5% of frequency in 16 of the 20 genes analyzed, of which 7 were novel. Biallelic disease-causing variants in genes with recessive inheritance were found in 5 PD cases (5.31%), whereas 13 patients (13.8%) carried likely pathogenic variants in genes with dominant inheritance. Moreover, 8 patients (8.5%) carried a single variant in MAPT or POLG, whereas co-occurrence of rare variants involving more than one gene was observed in 28 patients (30%). PD patients with variants in recessive genes had a younger mean age at onset than patients with dominant ones (33.40 (12.77) vs. 53.15 (6.63), p < 0.001), while their clinical features were similar. However, patients with rare variants in the risk factor genes or in more than one gene tended to have less resting tremor (p < 0.04), but more dystonia (p < 0.006) and dementia (p < 0.002) than those without any rare variants in known PD-associated genes. Our results showed a significant enrichment of rare variants particularly in LRRK2, VPS13C, POLG, and MAPT and underline their impact on the risk of sporadic form of the disease.
Collapse
Affiliation(s)
- Imane Smaili
- Research Team in Neurology and Neurogenetics, Center of Genomics of Human Pathologies, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco
| | - Houyam Tibar
- Department of Neurology and Neurogenetics, Specialties Hospital, CHU Ibn Sina, Rabat, Morocco
| | - Mounia Rahmani
- Research Team in Neurology and Neurogenetics, Center of Genomics of Human Pathologies, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco
- Department of Neurology and Neuropsychology, Specialties Hospital, CHU Ibn Sina, Rabat, Morocco
| | - Najlaa Machkour
- Department of Neurology and Neurogenetics, Specialties Hospital, CHU Ibn Sina, Rabat, Morocco
| | - Rachid Razine
- Laboratory of Biostatistics, Clinical and Epidemiological Research, Department of Public Health, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco
| | - Hajar Naciri Darai
- Department of Neurology and Neurogenetics, Specialties Hospital, CHU Ibn Sina, Rabat, Morocco
| | - Naima Bouslam
- Department of Neurology and Neurogenetics, Specialties Hospital, CHU Ibn Sina, Rabat, Morocco
| | - Ali Benomar
- Research Team in Neurology and Neurogenetics, Center of Genomics of Human Pathologies, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco
- Department of Neurology and Neurogenetics, Specialties Hospital, CHU Ibn Sina, Rabat, Morocco
| | - Wafa Regragui
- Research Team in Neurology and Neurogenetics, Center of Genomics of Human Pathologies, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco
- Department of Neurology and Neurogenetics, Specialties Hospital, CHU Ibn Sina, Rabat, Morocco
| | - Ahmed Bouhouche
- Research Team in Neurology and Neurogenetics, Center of Genomics of Human Pathologies, Medical School and Pharmacy, University Mohammed V in Rabat, Rabat, Morocco.
- Department of Neurology and Neurogenetics, Specialties Hospital, CHU Ibn Sina, Rabat, Morocco.
| |
Collapse
|
6
|
Daghi M, Lakhdar A, Otmani HE. Parkinson's disease research in Morocco: a review. Neurodegener Dis Manag 2023; 13:129-139. [PMID: 36803100 DOI: 10.2217/nmt-2022-0021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
Abstract
Aim: To quantify and provide an overview on the scientific productivity made by Moroccan academics in the research on Parkinson's disease (PD) and parkinsonism. Materials & methods: Scientific articles, in either English or French, were gathered from published literature in three recognized databases: PubMed, ScienceDirect and Scopus. Results: We identified 95 published papers from which 39 articles have been extracted after removing inadequate publications and duplications between databases. All articles were published between 2006 and 2021. The selected articles were subdivided into five categories. Conclusion: The Moroccan academia is presently facing a low productivity issues and a lack of research laboratories focusing on PD research. We anticipate that providing more budgetary funds will significantly improve the productivity of PD research.
Collapse
Affiliation(s)
- Mohamed Daghi
- Research Laboratory of Nervous System Diseases, Neurosensory Disorders & Disability, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, 20250, Morocco
| | - Abdelhakim Lakhdar
- Research Laboratory of Nervous System Diseases, Neurosensory Disorders & Disability, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, 20250, Morocco.,Department of Neurosurgery, Ibn Rochd University Hospital, Casablanca, 20360, Morocco
| | - Hicham El Otmani
- Laboratory of Medical Genetics & Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, 20250, Morocco.,Department of Neurology, Ibn Rochd University Hospital, Casablanca, 20360, Morocco
| |
Collapse
|
7
|
Lesage S, Mangone G, Tesson C, Bertrand H, Benmahdjoub M, Kesraoui S, Arezki M, Singleton A, Corvol JC, Brice A. Clinical Variability of SYNJ1-Associated Early-Onset Parkinsonism. Front Neurol 2021; 12:648457. [PMID: 33841314 PMCID: PMC8027075 DOI: 10.3389/fneur.2021.648457] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Accepted: 02/25/2021] [Indexed: 11/29/2022] Open
Abstract
Autosomal recessive early-onset parkinsonism is clinically and genetically heterogeneous. Mutations of three genes, PRKN, PINK1, and DJ-1 cause pure phenotypes usually characterized by levodopa-responsive Parkinson's disease. By contrast, mutations of other genes, including ATP13A2, PLA2G6, FBXO7, DNAJC6, SYNJ1, VPS13C, and PTRHD1, cause rarer, more severe diseases with a poor response to levodopa, generally with additional atypical features. We performed data mining on a gene panel or whole-exome sequencing in 460 index cases with early-onset (≤ 40 years) Parkinson's disease, including 57 with autosomal recessive disease and 403 isolated cases. We identified two isolated cases carrying biallelic mutations of SYNJ1 (double-heterozygous p.D791fs/p.Y232H and homozygous p. Y832C mutations) and two siblings with the recurrent homozygous p.R258Q mutation. All four variants were absent or rare in the Genome Aggregation Database, were predicted to be deleterious on in silico analysis and were found to be highly conserved between species. The patient with both the previously unknown p.D791fs and p.Y232H mutations presented with dystonia-parkinsonism accompanied by a frontal syndrome and oculomotor disturbances at the age of 39. In addition, two siblings from an Algerian consanguineous family carried the homozygous p.R258Q mutation and presented generalized tonic-clonic seizures during childhood, with severe intellectual disability, followed by progressive parkinsonism during their teens. By contrast, the isolated patient with the homozygous p. Y832C mutation, diagnosed at the age of 20, had typical parkinsonism, with no atypical symptoms and slow disease progression. Our findings expand the mutational spectrum and phenotypic profile of SYNJ1-related parkinsonism.
Collapse
Affiliation(s)
- Suzanne Lesage
- Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, CIC Neurosciences, Paris, France
| | - Graziella Mangone
- Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, CIC Neurosciences, Paris, France
| | - Christelle Tesson
- Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, CIC Neurosciences, Paris, France
| | - Hélène Bertrand
- Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, CIC Neurosciences, Paris, France
| | | | | | | | - Andrew Singleton
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, United States
| | - Jean-Christophe Corvol
- Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, CIC Neurosciences, Paris, France
| | - Alexis Brice
- Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, CIC Neurosciences, Paris, France
| |
Collapse
|
8
|
Paesmans J, Martin E, Deckers B, Berghmans M, Sethi R, Loeys Y, Pardon E, Steyaert J, Verstreken P, Galicia C, Versées W. A structure of substrate-bound Synaptojanin1 provides new insights in its mechanism and the effect of disease mutations. eLife 2020; 9:64922. [PMID: 33349335 PMCID: PMC7781601 DOI: 10.7554/elife.64922] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Accepted: 12/16/2020] [Indexed: 12/13/2022] Open
Abstract
Synaptojanin1 (Synj1) is a phosphoinositide phosphatase, important in clathrin uncoating during endocytosis of presynaptic vesicles. It was identified as a potential drug target for Alzheimer's disease, Down syndrome, and TBC1D24-associated epilepsy, while also loss-of-function mutations in Synj1 are associated with epilepsy and Parkinson's disease. Despite its involvement in a range of disorders, structural, and detailed mechanistic information regarding the enzyme is lacking. Here, we report the crystal structure of the 5-phosphatase domain of Synj1. Moreover, we also present a structure of this domain bound to the substrate diC8-PI(3,4,5)P3, providing the first image of a 5-phosphatase with a trapped substrate in its active site. Together with an analysis of the contribution of the different inositide phosphate groups to catalysis, these structures provide new insights in the Synj1 mechanism. Finally, we analysed the effect of three clinical missense mutations (Y793C, R800C, Y849C) on catalysis, unveiling the molecular mechanisms underlying Synj1-associated disease.
Collapse
Affiliation(s)
- Jone Paesmans
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Ella Martin
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Babette Deckers
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Marjolijn Berghmans
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Ritika Sethi
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Yannick Loeys
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Els Pardon
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Jan Steyaert
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Patrik Verstreken
- VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.,KU Leuven, Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
| | - Christian Galicia
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Wim Versées
- VIB-VUB Center for Structural Biology, Brussels, Belgium.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
9
|
Abstract
Parkinson’s Disease (PD) is a complex neurodegenerative disorder that mainly results due to the loss of dopaminergic neurons in the substantia nigra of the midbrain. It is well known that dopamine is synthesized in substantia nigra and is transported to the striatumvianigrostriatal tract. Besides the sporadic forms of PD, there are also familial cases of PD and number of genes (both autosomal dominant as well as recessive) are responsible for PD. There is no permanent cure for PD and to date, L-dopa therapy is considered to be the best option besides having dopamine agonists. In the present review, we have described the genes responsible for PD, the role of dopamine, and treatment strategies adopted for controlling the progression of PD in humans.
Collapse
|
10
|
Lesage S, Lunati A, Houot M, Romdhan SB, Clot F, Tesson C, Mangone G, Toullec BL, Courtin T, Larcher K, Benmahdjoub M, Arezki M, Bouhouche A, Anheim M, Roze E, Viallet F, Tison F, Broussolle E, Emre M, Hanagasi H, Bilgic B, Tazir M, Djebara MB, Gouider R, Tranchant C, Vidailhet M, Le Guern E, Corti O, Mhiri C, Lohmann E, Singleton A, Corvol JC, Brice A. Characterization of Recessive Parkinson Disease in a Large Multicenter Study. Ann Neurol 2020; 88:843-850. [PMID: 33045815 DOI: 10.1002/ana.25787] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 05/17/2020] [Accepted: 05/18/2020] [Indexed: 12/26/2022]
Abstract
Studies of the phenotype and population distribution of rare genetic forms of parkinsonism are required, now that gene-targeting approaches for Parkinson disease have reached the clinical trial stage. We evaluated the frequencies of PRKN, PINK1, and DJ-1 mutations in a cohort of 1,587 cases. Mutations were found in 14.1% of patients; 27.6% were familial and 8% were isolated. PRKN was the gene most frequently mutated in Caucasians, whereas PINK1 mutations predominated in Arab-Berber individuals. Patients with PRKN mutations had an earlier age at onset, and less asymmetry, levodopa-induced motor complications, dysautonomia, and dementia than those without mutations. ANN NEUROL 2020;88:843-850.
Collapse
Affiliation(s)
- Suzanne Lesage
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France
| | - Ariane Lunati
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France
| | - Marion Houot
- Institute of Memory and Alzheimer's Disease, Center of Excellence for Neurodegenerative Diseases, Public Hospital Network of Paris, Department of Neurology, Pitié-Salpêtrière Hospital, University of Paris 6, Paris, France.,Clinical Investigation Center, Pitié Neurosciences CIC-1422, Paris, France
| | - Sawssan Ben Romdhan
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France.,Research Unit in Neurogenetics, Clinical Investigation Center, Habib Bourguiba University Hospital Center, Sfax, Tunisia
| | - Fabienne Clot
- Functional Unit of Molecular and Cellular Neurogenetics, Department of Genetics, Public Hospital Network of Paris, University Hospitals of La Pitié Salpêtrière-Charles Foix, Paris, France
| | - Christelle Tesson
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France
| | - Graziella Mangone
- Clinical Investigation Center, Pitié Neurosciences CIC-1422, Paris, France
| | | | - Thomas Courtin
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France
| | - Kathy Larcher
- Functional Unit of Molecular and Cellular Neurogenetics, Department of Genetics, Public Hospital Network of Paris, University Hospitals of La Pitié Salpêtrière-Charles Foix, Paris, France
| | | | - Mohamed Arezki
- Frantz Fanon Hospital, University Hospital Center of Blida, Blida, Algeria
| | - Ahmed Bouhouche
- Research Unit in Neurology and Neurogenetics, Department of Neurology B and Neurogenetics, Faculty of Medicine and Pharmacy, Specialty Hospital ONO, Mohammed V University, Rabat, Morocco
| | - Mathieu Anheim
- Department of Neurology, University Hospitals of Strasbourg, Strasbourg, France.,Institute of Genetics and Molecular and Cellular Biology, Illkirch, France.,Federation of Translational Medicine of Strasbourg, University of Strasbourg, Strasbourg, France
| | - Emmanuel Roze
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France.,Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France
| | - François Viallet
- Department of Neurology, Intercommunal Hospital Center of Aix-Pertuis, Aix-en-Provence, France.,Department of Speech and Language, Research Unit UMR 7309, French National Center for Scientific Research and University of Aix-Marseille, Aix-en-Provence, France
| | - François Tison
- Department of Neurology, Pellegrin Hospital, University Hospital Center of Bordeaux, Bordeaux, France.,Institute of Neurodegenerative Diseases, University of Bordeaux, Bordeaux, France.,Research Unit UMR 5293, French National Center for Scientific Research, Bordeaux, France
| | - Emmanuel Broussolle
- Research Unit UMR 5229, Marc-Jeannerod Institute of Cognitive Science, French National Center for Scientific Research, University of Lyon, Bron, France.,Department of Neurology C, Civil Hospices of Lyon, Pierre-Wertheimer Neurological Hospital, Bron, France.,Faculty of Medicine Lyon-Sud Charles-Mérieux, University of Lyon, Oullins, France
| | - Murat Emre
- Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Hasmet Hanagasi
- Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Basar Bilgic
- Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Meriem Tazir
- Department of Neurology, Mustapha Bacha University Hospital, Algiers, Algeria
| | - Mouna Ben Djebara
- Department of Neurology, Faculty of Medicine of Tunis, Clinical Investigation Center, Razi University Hospital, Tunis, Tunisia
| | - Riadh Gouider
- Department of Neurology, Faculty of Medicine of Tunis, Clinical Investigation Center, Razi University Hospital, Tunis, Tunisia
| | - Christine Tranchant
- Department of Neurology, University Hospitals of Strasbourg, Strasbourg, France.,Institute of Genetics and Molecular and Cellular Biology, Illkirch, France.,Federation of Translational Medicine of Strasbourg, University of Strasbourg, Strasbourg, France
| | - Marie Vidailhet
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France.,Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France
| | - Eric Le Guern
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France.,Functional Unit of Molecular and Cellular Neurogenetics, Department of Genetics, Public Hospital Network of Paris, University Hospitals of La Pitié Salpêtrière-Charles Foix, Paris, France
| | - Olga Corti
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France
| | - Chokri Mhiri
- Research Unit in Neurogenetics, Clinical Investigation Center, Habib Bourguiba University Hospital Center, Sfax, Tunisia
| | - Ebba Lohmann
- Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.,Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
| | - Andrew Singleton
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland
| | - Jean-Christophe Corvol
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France.,Clinical Investigation Center, Pitié Neurosciences CIC-1422, Paris, France
| | - Alexis Brice
- Research Unit UMR 1127, Sorbonne University, Paris, France.,Research Unit U1127, National Institute of Health and Medical Research, Paris, France.,Research Unit UMR 7225, the French National Center for Scientific Research, Paris, France.,Institute for Brain and Spinal Cord, Paris, France
| | | |
Collapse
|
11
|
Lesage S, Houot M, Mangone G, Tesson C, Bertrand H, Forlani S, Anheim M, Brefel-Courbon C, Broussolle E, Thobois S, Damier P, Durif F, Roze E, Tison F, Grabli D, Ory-Magne F, Degos B, Viallet F, Cormier-Dequaire F, Ouvrard-Hernandez AM, Vidailhet M, Lohmann E, Singleton A, Corvol JC, Brice A. Genetic and Phenotypic Basis of Autosomal Dominant Parkinson's Disease in a Large Multi-Center Cohort. Front Neurol 2020; 11:682. [PMID: 32849182 PMCID: PMC7399219 DOI: 10.3389/fneur.2020.00682] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Accepted: 06/08/2020] [Indexed: 12/20/2022] Open
Abstract
LRRK2, SNCA, and VPS35 are unequivocally associated with autosomal dominant Parkinson's disease (PD). We evaluated the prevalence of LRRK2, SNCA, and VPS35 mutations and associated clinical features in a large French multi-center cohort of PD patients. Demographic and clinical data were collected for 1,805 index cases (592 with autosomal dominant inheritance and 1,213 isolated cases) since 1990. All probands were screened with TaqMan assays for LRRK2 Gly2019Ser. In the absence of this mutation, the coding sequences of the three genes were analyzed by Sanger sequencing and/or next-generation sequencing. The data for the three genes were analyzed according to age at onset, family history, ethnic origin and clinical features. We identified 160 index cases (8.9%) with known pathogenic variants: 138 with pathogenic LRRK2 variants (7.6%), including 136 with the Gly2019Ser mutation, 19 with SNCA point mutations or genomic rearrangements (1.1%), and three with the VPS35 Asp620Asn mutation (0.16%). Mutation frequencies were higher in familial than isolated cases, consistent with autosomal dominant inheritance (12.0 vs. 7.3%; OR 1.7, 95% CI [1.2-2.4], p = 0.001). PD patients with LRRK2 variants were more likely to have higher rates of late-onset PD (>50 years; OR 1.5, 95% CI [1.0-2.1], p = 0.03), whereas those with SNCA mutations tended to have earlier age at onset disease (≤ 50 years, p = 0.06). The clinical features of LRRK2 carriers and those without any pathogenic variants in known PD-associated genes were similar. The likelihood of detecting disease-causing mutations was higher in cases compatible with autosomal dominant inheritance.
Collapse
Affiliation(s)
- Suzanne Lesage
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
| | - Marion Houot
- Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), Centre d'Excellence sur les Maladies Neurodégénératives (CoEN), Assistance Publique – Hôpitaux de Paris (AP-HP), Département de Neurologie, Groupe Hospitalier Pitié-Salpêtrière, Université Paris 6, Paris, France
- Centre d'Investigation Clinique Pitié Neurosciences CIC-1422, Paris, France
| | - Graziella Mangone
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
- Centre d'Investigation Clinique Pitié Neurosciences CIC-1422, Paris, France
| | - Christelle Tesson
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
| | - Hélène Bertrand
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
| | - Sylvie Forlani
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
| | - Mathieu Anheim
- Département de Neurologie aux Hôpitaux Universitaires de Strasbourg, Strasbourg, France
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - Christine Brefel-Courbon
- Service de Pharmacologie Clinique, Faculté de Médecine, Hôpital Universitaire, Toulouse, France
- Service de Neurologie B8, Hôpital Pierre Paul Riquet, Hôpital Universitaire, Toulouse, France
| | - Emmanuel Broussolle
- Université de Lyon, Institut des Sciences Cognitives Marc-Jeannerod, Unité Mixte de Recherche (UMR) 5229, Centre National de la Recherche Scientifique (CNRS), Bron, France
- Hospices Civils de Lyon, Hôpital Neurologique Pierre-Wertheimer, Département de Neurologie C, Bron, France
- Université de Lyon, Faculté de Médecine Lyon-Sud Charles-Mérieux, Oullins, France
| | - Stéphane Thobois
- Université de Lyon, Institut des Sciences Cognitives Marc-Jeannerod, Unité Mixte de Recherche (UMR) 5229, Centre National de la Recherche Scientifique (CNRS), Bron, France
- Hospices Civils de Lyon, Hôpital Neurologique Pierre-Wertheimer, Département de Neurologie C, Bron, France
- Université de Lyon, Faculté de Médecine Lyon-Sud Charles-Mérieux, Oullins, France
| | - Philippe Damier
- Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique, Nantes, France
| | - Franck Durif
- Département de Neurologie A, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Emmanuel Roze
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
- Département de Neurologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - François Tison
- Institut des Maladies Neurodégénératives, Centre Hospitalier Universitaire et Université de Bordeaux, Bordeaux, France
| | - David Grabli
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
- Centre d'Investigation Clinique Pitié Neurosciences CIC-1422, Paris, France
| | - Fabienne Ory-Magne
- Centre de Neuroimagerie de Toulouse, Université de Toulouse - Institut National de la Santé et de la Recherche Médicale (INSERM) - Université de Toulouse, Toulouse, France
- Centre des Neurosciences, Hôpital Universitaire de Toulouse, Toulouse, France
| | - Bertrand Degos
- Unité de Neurologie, Hôpital Universitaire Avicenne, Hôpitaux Universitaires de Paris-Seine Saint Denis, Assistance Publique – Hôpitaux de Paris (AP-HP), Sorbonne Paris Nord, Bobigny, France
- Equipe Dynamique et Physiopathologie des Réseaux Neuronaux, Centre pour la Recherche Interdisciplinaire en Biologie, Collège de France, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 7241, Institut National de la Santé et de la Recherche Médicale (INSERM) U1050, Labex MemoLife, Paris, France
| | - François Viallet
- Département de Neurologie, Centre Hospitalier Intercommunal d'Aix-Pertuis, Aix-en-Provence, France
- Laboratoire Parole et Langage, Unité Mixte de Recherche (UMR) 7309, Centre National de la Recherche Scientifique (CNRS) et Université d'Aix-Marseille, Aix-en-Provence, France
| | - Florence Cormier-Dequaire
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
- Centre d'Investigation Clinique Pitié Neurosciences CIC-1422, Paris, France
| | | | - Marie Vidailhet
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
- Département de Neurologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Ebba Lohmann
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
| | - Andrew Singleton
- Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, United States
| | - Jean-Christophe Corvol
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
- Centre d'Investigation Clinique Pitié Neurosciences CIC-1422, Paris, France
| | - Alexis Brice
- Sorbonne Université, Unité Mixte de Recherche (UMR) 1127, Paris, France
- Unité de Recherche U1127 à l'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- Unité de Recherche Unité Mixte de Recherche (UMR) 7225 au Centre National de la Recherche Scientifique (CNRS), Paris, France
- Institut du Cerveau (ICM), Paris, France
| | | |
Collapse
|
12
|
Wan SX, Pan X, Qian JJ, Shu Y, Xu P, Zhao J, Gong QX, Yin JT. Downregulation of ATP13A2 in midbrain dopaminergic neurons is related to defective autophagy in a mouse model of Parkinson's disease. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2020; 13:1853-1858. [PMID: 32782714 PMCID: PMC7414488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Accepted: 04/14/2020] [Indexed: 06/11/2023]
Abstract
Parkinson's disease (PD) is one of the most common diseases of the nervous system characterized by movement disorders arising from loss of midbrain dopaminergic neurons. The relationship between PD and autophagy has received considerable attention. This study aimed to investigate the involvement of the ATP13A2 gene in damage of dopaminergic neurons induced by abnormal autophagy in a MPTP-induced PD mouse model. MPTP was intraperitoneally injected into C57BL mice at 40 mg/kg for 7 days in experimental group. Saline was injected into mice in the control group. After the injection, the mice were tested at different time points for abnormal limb movement by a swimming test. The brain tissue was collected on day 1, 5, and 7 to measure concentration of intracellular calcium. The expression of ATP13A2 was evaluated by real-time PCR. The expression of α-synclein, LC3, LAMP-2, and CaMKK protein was detected by western blot. We found significant motor dysfunction on day 7 in the experimental group, and the expression of α-synclein in the substantia nigra of the midbrain was significantly increased while the expression of ATP13A2 gene was reduced significantly compared with the control group. The concentration of intracellular calcium in the experimental group was significantly higher than in the control group. Autophagy associated proteins LC3-II and LAMP-2 were downregulated and CaMKK protein was upregulated in midbrain tissues of the experimental group compared to control group. In conclusion, our findings suggest that decreased expression of ATP13A2 may lead to defective autophagy and damage to midbrain dopaminergic neurons.
Collapse
Affiliation(s)
- Sheng-Xia Wan
- The Fourth Affiliated Hospital of Jiangsu UniversityZhenjiang, China
| | - Xin Pan
- Department of Emergency, Zhenjiang Emergency CenterZhenjiang, China
| | - Jin-Jun Qian
- The Fourth Affiliated Hospital of Jiangsu UniversityZhenjiang, China
| | - Yu Shu
- The Fourth Affiliated Hospital of Jiangsu UniversityZhenjiang, China
| | - Ping Xu
- The Fourth Affiliated Hospital of Jiangsu UniversityZhenjiang, China
| | - Jing Zhao
- The Fourth Affiliated Hospital of Jiangsu UniversityZhenjiang, China
| | - Qi-Xia Gong
- The Fourth Affiliated Hospital of Jiangsu UniversityZhenjiang, China
| | - Jiang-Tao Yin
- Critical Care Unit, Affiliated Hospital of Jiangsu UniversityZhenjiang, China
| |
Collapse
|
13
|
Gene Panel Sequencing Identifies Novel Pathogenic Mutations in Moroccan Patients with Familial Parkinson Disease. J Mol Neurosci 2020; 71:142-152. [PMID: 32557143 DOI: 10.1007/s12031-020-01635-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2020] [Accepted: 06/12/2020] [Indexed: 10/24/2022]
Abstract
In the past two decades, genetic studies of familial forms of Parkinson's disease (PD) have shown evidence that PD has a significant genetic component. Indeed, 12 genes are strongly involved in PD causality, three of them having dominant inheritance and 9 causing early-onset autosomal recessive forms, including 3 with a typical PD and 6 with an atypical parkinsonism. The aim of this study was to determine the genetic basis of familial PD in Moroccan patients. We selected 18 Moroccan index case with familial forms of PD. Patients were first screened for exon-rearrangements by MLPA kit. They were then analyzed by gene panel next-generation sequencing (NGS). Functional variants with minor allele frequencies < 0.5% in public databases were considered potential candidate variants to PD. In the 18 PD patients with a positive family history that were analyzed, MLPA assays identified PRKN deletions in two patients: a homozygous exon 3-5 deletion and a heterozygous exon 4 deletion. Sixteen rare SNV were identified by NGS, four of them were novel. Seven mutations were categorized as pathogenic, five as likely pathogenic, two to be of uncertain significance, and 3 were predicted to be likely benign but may give a weaker pathogenic effect and could contribute to PD since they were found in late-onset PD patients. Rare or novel mutations that could be related to the disease were identified in 72% of these patients (13/18), including nine with bi-allelic pathogenic/likely pathogenic variants in genes causing recessive PD, particularly PRKN and PINK1. Mutations in genes with dominant inheritance were found in 4/18 patients (22%).
Collapse
|
14
|
Amodio G, Moltedo O, Fasano D, Zerillo L, Oliveti M, Di Pietro P, Faraonio R, Barone P, Pellecchia MT, De Rosa A, De Michele G, Polishchuk E, Polishchuk R, Bonifati V, Nitsch L, Pierantoni GM, Renna M, Criscuolo C, Paladino S, Remondelli P. PERK-Mediated Unfolded Protein Response Activation and Oxidative Stress in PARK20 Fibroblasts. Front Neurosci 2019; 13:673. [PMID: 31316342 PMCID: PMC6610533 DOI: 10.3389/fnins.2019.00673] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 06/12/2019] [Indexed: 12/20/2022] Open
Abstract
PARK20, an early onset autosomal recessive parkinsonism is due to mutations in the phosphatidylinositol-phosphatase Synaptojanin 1 (Synj1). We have recently shown that the early endosomal compartments are profoundly altered in PARK20 fibroblasts as well as the endosomal trafficking. Here, we report that PARK20 fibroblasts also display a drastic alteration of the architecture and function of the early secretory compartments. Our results show that the exit machinery from the Endoplasmic Reticulum (ER) and the ER-to-Golgi trafficking are markedly compromised in patient cells. As a consequence, PARK20 fibroblasts accumulate large amounts of cargo proteins within the ER, leading to the induction of ER stress. Interestingly, this stressful state is coupled to the activation of the PERK/eIF2α/ATF4/CHOP pathway of the Unfolded Protein Response (UPR). In addition, PARK20 fibroblasts reveal upregulation of oxidative stress markers and total ROS production with concomitant alteration of the morphology of the mitochondrial network. Interestingly, treatment of PARK20 cells with GSK2606414 (GSK), a specific inhibitor of PERK activity, restores the level of ROS, signaling a direct correlation between ER stress and the induction of oxidative stress in the PARK20 cells. All together, these findings suggest that dysfunction of early secretory pathway might contribute to the pathogenesis of the disease.
Collapse
Affiliation(s)
- Giuseppina Amodio
- Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy
| | - Ornella Moltedo
- Department of Pharmacy, University of Salerno, Salerno, Italy
| | - Dominga Fasano
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - Lucrezia Zerillo
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - Marco Oliveti
- Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy
| | - Paola Di Pietro
- Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy
| | - Raffaella Faraonio
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - Paolo Barone
- Section of Neuroscience, Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy
| | - Maria Teresa Pellecchia
- Section of Neuroscience, Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy
| | - Anna De Rosa
- Department of Neuroscience, Reproductive, and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy
| | - Giuseppe De Michele
- Department of Neuroscience, Reproductive, and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy
| | | | | | | | - Lucio Nitsch
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - Giovanna Maria Pierantoni
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - Maurizio Renna
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - Chiara Criscuolo
- Department of Neuroscience, Reproductive, and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy
| | - Simona Paladino
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - Paolo Remondelli
- Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy
| |
Collapse
|
15
|
Wang Z, Gao G, Duan C, Yang H. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease. Biomed Pharmacother 2019; 115:108843. [PMID: 31055236 DOI: 10.1016/j.biopha.2019.108843] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 03/14/2019] [Accepted: 03/31/2019] [Indexed: 12/12/2022] Open
Abstract
Many neurodegenerative diseases are characterized by progressive loss of neurons and abnormal protein accumulation, including amyloid (A)β and tau in Alzheimer's disease and Lewy bodies and α-synuclein (α-syn) in Parkinson's disease (PD). Recent evidence suggests that adaptive immunity plays an important role in PD, and that anti-α-syn antibodies can be used as therapy in neurodegenerative diseases; monoclonal antibodies were shown to inhibit α-syn propagation and aggregation in PD models and patients. In this review, we summarize the different pathological states of α-syn, including gene mutations, truncation, phosphorylation, and the high molecular weight form, and describe the specific antibodies that recognize the α-syn monomer or oligomer, some of which have been tested in clinic trials. We also discuss future research directions and potential targets in PD therapy.
Collapse
Affiliation(s)
- Zhipeng Wang
- Department of Neurobiology School of Basic Medical Sciences, Center of Parkinson Disease Beijing Institute for Brain Disorders, Beijing Key Laboratory for Neural Regeneration and Repair, Beijing Key Laboratory on Parkinson's Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Capital Medical University, Beijing, 100069, China
| | - Ge Gao
- Department of Neurobiology School of Basic Medical Sciences, Center of Parkinson Disease Beijing Institute for Brain Disorders, Beijing Key Laboratory for Neural Regeneration and Repair, Beijing Key Laboratory on Parkinson's Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Capital Medical University, Beijing, 100069, China
| | - Chunli Duan
- Department of Neurobiology School of Basic Medical Sciences, Center of Parkinson Disease Beijing Institute for Brain Disorders, Beijing Key Laboratory for Neural Regeneration and Repair, Beijing Key Laboratory on Parkinson's Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Capital Medical University, Beijing, 100069, China
| | - Hui Yang
- Department of Neurobiology School of Basic Medical Sciences, Center of Parkinson Disease Beijing Institute for Brain Disorders, Beijing Key Laboratory for Neural Regeneration and Repair, Beijing Key Laboratory on Parkinson's Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Capital Medical University, Beijing, 100069, China.
| |
Collapse
|
16
|
Clonazepam improves the symptoms of two siblings with novel variants in the SYNJ1 gene. Parkinsonism Relat Disord 2018; 62:221-225. [PMID: 30473187 DOI: 10.1016/j.parkreldis.2018.11.020] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 11/15/2018] [Accepted: 11/17/2018] [Indexed: 11/23/2022]
Abstract
BACKGROUND Mutations in the SYNJ1 gene have been associated with early-onset of atypical Parkinson's disease or severe neurodegeneration with intractable seizures. Due to the rarity of the disease, there were limitations in the quality of available treatment options for SYNJ1-related diseases. METHODS Two affected siblings from a non-consanguineous family were evaluated through a set of clinical and laboratory tests. The genetic screening was performed through exome next generation sequencing. SYNJ1 mutant transcripts were purified and cloned into the vectors for Sanger sequence of single-stranded DNA. Relative level of the SYNJ1 transcript was measured by quantitative PCR. RESULTS The clinical features were characterized by a triad of symptomatic progression including diplopia, dystonia, and Parkinsonism. The dystonic symptoms were outstanding in the siblings, which preceded the Parkinsonism symptoms and became the main symptoms. Clonazepam resolved the clinical symptoms, especially the severe trunk dystonia and dystonic postures of limbs. Compound heterozygous variants (c.2579-2A > G; p.A860Gfs*5 and c.3845C > A; p.P1282L) were identified in the SYNJ1 gene co-segregating in this family. The proline residue is highly conserved across species and predicted to be damaging by several in silico tools. The splice site variant caused a skip of exon 20 and a significant reduction of the SYNJ1 transcript expression. CONCLUSIONS Our study expanded the clinical and genetic spectrums of the SYNJ1-related diseases. Although our study was a preliminary observation, it indicated that clonazepam could improve the dystonic symptoms caused by mutations in the SYNJ1 gene.
Collapse
|